- The USPTO issues U.S. Patent No. 9,877,990 to Krystal Biotech (NASDAQ:KRYS +0.4%) covering compositions comprising herpes simplex viral (HSV) vectors and methods of using the compositions to treat or prevent skin wounds and disorders.
- The company's lead candidate is preclinical-stage KB103, a gene therapy to treat dystrophic epidermolysis bullosa, an inherited disorder characterized by skin blistering due to the lack of collagen. It is a replication-defective, non-integrating HSV-1 viral vector developed under the company's STAR-D platform that delivers genes that code for collagen directly to skin cells.